Advertisement

Topics

Latest "Somna Therapeutics LLC" News Stories

23:11 EST 13th December 2018 | BioPortfolio

Here are the most relevant search results for "Somna Therapeutics LLC" found in our extensive news archives from over 250 global news sources.

More Information about Somna Therapeutics LLC on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Somna Therapeutics LLC for you to read. Along with our medical data and news we also list Somna Therapeutics LLC Clinical Trials, which are updated daily. BioPortfolio also has a large database of Somna Therapeutics LLC Companies for you to search.

Showing "Somna Therapeutics" News Articles 1–25 of 8,100+

Thursday 13th December 2018

National Call to Companies for Applications to Present at the OBIO 2019 Niagara Investment Summit

The OBIO 2019 Niagara Investment Summit national call for applications from health science companies that are seeking Series A or beyond investments is now open. On February 20-22, 2019, the Summit will bring 30 of Canada’s most promising health science companies to Niagara-on-the-Lake to present to and meet with global investors. This year’s ...


The global digital therapeutics market is expected to reach US$ 8,941. ...

NEW YORK, Dec. 13, 2018 /PRNewswire/ -- The global digital therapeutics market is expected to reach US$ 8,941.1 Mn by 2025 from US$ 1,993.2 Mn Read more...

Hepcidin Antagonist Pipeline Insight Report 2018 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Hepcidin Antagonist -Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering. ‘Hepcidin Antagonist – Pipeline Insight, 2018’ report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Hepcidin Antagonist development. The R...


Shield expecting US decision on Feraccru in July

Shield Therapeutics has revealed that the US Food and Drug Administration will make a decision on its application to market Feraccru in the US by July 27 next year.

Rubius Therapeutics Inc RUBY Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250

SummaryRubius Therapeutics Inc Rubius Therapeutics is a biotechnology company that focuses on the development of medicines for the treatment of rare diseases, cancer and autoimmune diseases. The company through its rubius erythrocyte design RED platform engineer and culture Red Cell Therapeutics RCT product candidates. Its products under development are intended for the treatment of phenylketonuri...

HIV Attachment Inhibitor Pipeline Insights Report 2018 Featuring Bristol-Myers Squibb, HSRx Biopharmaceutical, Osel Inc & AnGes MG – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “HIV Attachment Inhibitor – Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering. ‘HIV Attachment Inhibitor – Pipeline Insight, 2018’ report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across HIV … Continue rea...

Bioasis to Present at Investor & Industry Conferences in January 2019

Bioasis Technologies Inc. (TSX.V:BTI)(OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of

Verrucous Carcinoma Global Clinical Trials Review, H2, 2018 [Report Updated: 28092018] Prices from USD $2125

Verrucous Carcinoma Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, Verrucous Carcinoma Global Clinical Trials Review, H2, 2018" provides an overview of Verrucous Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Verrucous Carcinoma. Report includes an overview of trial numbers and their average enrollment in...

Orchard Therapeutics to Build New Gene Therapy Manufacturing Facility in California

NewsBuild-out is expected to begin in 2019 and ongoing plans call for adding more than100 full-time employees over the next few years.

CORRECTING and REPLACING Adaptive Phage Therapeutics Enters into Collaboration Agreement with Researchers at Yale University to Manufacture and Supply Therapeutic Bacteriophage

Second paragraph, first sentence of release dated December 12, 2018, should read: ... Food and Drug Administration (instead of...Federal Drug Administration). The corrected release reads: ADAPTIVE PHAGE THERAPEUTICS ENTERS INTO COLLABORATION AGREEMENT WITH RESEARCHERS AT YALE UNIVERSITY TO MANUFACTURE AND SUPPLY THERAPEUTIC BACTERI...

Short Bowel Syndrome Global Clinical Trials Review, H2, 2018 [Report Updated: 31072018] Prices from USD $2125

Short Bowel Syndrome Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, Short Bowel Syndrome Global Clinical Trials Review, H2, 2018" provides an overview of Short Bowel Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Short Bowel Syndrome. Report includes an overview of trial numbers and their average enrollmen...

Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing’s Syndrome

Corcept Therapeutics (NASDAQ:CORT) announced today that the United States Patent and Trademark Office has given notice that it will allow a patent covering the concomitant use of Korlym® and drugs from the class of medications known as strong CYP3A inhibitors to treat patients with hypercortisolism (Cushing’s syndrome).  The patent will expire in 2037. As quoted in … Continued The post ...

NHMRC to Fund Major Phase 2 Clinical Trial of Cynata’s Cymerus MSCs in Patients with Osteoarthritis

Cynata Therapeutics (ASX:CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that the Australian National Health and Medical Research Council (NHMRC) has approved a grant to fund a Phase 2 clinical trial to evaluate Cynata’s Cymerus mesenchymal stem cells (MSCs) as a treatment for osteoarthritis. As quoted in the press release: … Continued...

Prostatic Intraepithelial Neoplasia Global Clinical Trials Review, H1, 2018 [Report Updated: 29062018] Prices from USD $2125

Prostatic Intraepithelial Neoplasia Global Clinical Trials Review, H1, 2018SummaryGlobalData's clinical trial report, Prostatic Intraepithelial Neoplasia Global Clinical Trials Review, H1, 2018" provides an overview of Prostatic Intraepithelial Neoplasia clinical trials scenario. This report provides top line data relating to the clinical trials on Prostatic Intraepithelial Neoplasia. Report inclu...

Traumatic Brain Injury Global Clinical Trials Review, H2, 2018 [Report Updated: 31082018] Prices from USD $2125

Traumatic Brain Injury Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, Traumatic Brain Injury Global Clinical Trials Review, H2, 2018" provides an overview of Traumatic Brain Injury clinical trials scenario. This report provides top line data relating to the clinical trials on Traumatic Brain Injury. Report includes an overview of trial numbers and their average e...

Orchard Therapeutics to Build Out Gene Therapy Manufacturing Site in Fremont, CA

Orchard Therapeutics said it will build out a gene therapy manufacturing facility in Fremont, CA, that will employ 100 people and expand its manufacturing capabilities to support plans for an expanded pipeline. The new facility, Orchard said, will enhance its capacity to develop and deliver lentiviral vector and gene-corrected hematopoetic stem cells for a wide […] The post Orchard Therapeut...

Generic Version of Evzio Opioid Overdose Med to Debut With Reduced List Price

NewsOffered through Kaléo subsidiary IJ Therapeutics, the authorized generic will be made available in midyear 2019 at $178 per carton.

Dragonfly Therapeutics Announces Celgene In-license of First Two TriNKET Immunotherapy Drug Candidates

Celgene licenses two TriNKET immunotherapy drug candidates built by Dragonfly for $24m plus milestones and royalties WALTHAM, Massachusetts, Dec. 13, 2018 /PRNewswire/ -- Dragonfly Therapeutics, I...

Third Rock Ventures Names Christoph Lengauer, Ph.D., and Jeffrey Tong, Ph.D., as Partners

- Scientific and strategic leaders bring significant operating experience to the firm’s company creation mission - Third Rock Ventures LLC today announced that Christoph Lengauer, Ph.D., and Jeffrey Tong, Ph.D., have joined as partners. Both were previously venture partners at the firm. To date, Third Rock has invested in or launched ...

Dragonfly Therapeutics Announces $CELG In-license of First Two TriNKET™ Immunotherapy Drug Candidates https://www.prnewswire.com/news-releases/dragonfly-therapeutics-announces-celgene-in-license-of-first-two-trinket-immunotherapy-drug-candidates-3007650

Dragonfly Therapeutics Announces $CELG In-license of First Two TriNKET™ Immunotherapy Drug Candidates https://www.prnewswire.com/news-releases/dragonfly-therapeutics-announces-celgene-in-license-of-first-two-trinket-immunotherapy-drug-candidates-300765057.html …

Sciatica Global Clinical Trials Review, H2, 2018 [Report Updated: 31072018] Prices from USD $2125

Sciatica Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, Sciatica Global Clinical Trials Review, H2, 2018" provides an overview of Sciatica clinical trials scenario. This report provides top line data relating to the clinical trials on Sciatica. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. T...

Psoriasis Global Clinical Trials Review, H1, 2018 [Report Updated: 29062018] Prices from USD $2125

Psoriasis Global Clinical Trials Review, H1, 2018SummaryGlobalData's clinical trial report, Psoriasis Global Clinical Trials Review, H1, 2018" provides an overview of Psoriasis clinical trials scenario. This report provides top line data relating to the clinical trials on Psoriasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the glob...

$AKBA $KERX Complete Merger, Creating Fully Integrated Renal Company https://www.businesswire.com/news/home/20181213005206/en/Akebia-Therapeutics-Keryx-Biopharmaceuticals-Complete-Merger-Creating …

$AKBA $KERX Complete Merger, Creating Fully Integrated Renal Company https://www.businesswire.com/news/home/20181213005206/en/Akebia-Therapeutics-Keryx-Biopharmaceuticals-Complete-Merger-Creating …

Foghorn® Therapeutics appoints Carl P. Decicco, Ph.D. as Chief Scientific Officer

Decicco also to become Venture Partner at Flagship Pioneering Foghorn® Therapeutics Inc. (Foghorn), a discoverer and developer of new medicines based on insights into genetic mutations in the chromatin regulatory system, and Flagship Pioneering, a unique life science innovation enterprise, today announced the appointment of Carl P. Decicco, Ph.D., as ...

Akebia Therapeutics and Keryx Biopharmaceuticals Complete Merger, Creating Fully Integrated Renal Company

Akebia Therapeutics, Inc. (Nasdaq:AKBA) and Keryx Biopharmaceuticals, Inc. today announced the successful completion of their previously announced merger. "We are very pleased to announce the completion of our merger with Keryx to create a fully integrated renal company that has the potential to set new standards of care for patients with kid...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks